All-In Podcast

E43: Innovative venture strategies, Zymergen's implosion, Square acquires Afterpay & more

Chamath Palihapitiya on venture Studios, Deep Tech Busts, and Fintech Power Plays Unpacked.

Chamath PalihapitiyahostDavid SackshostJason CalacanishostDavid FriedberghostJason CalacanishostChamath PalihapitiyahostChamath PalihapitiyahostDavid Sackshost
Aug 6, 20211h 31m
The Production Board venture studio model, funding structure, and focus on synthetic biologyCraft Ventures’ new $1.12B fund and incubation approach (e.g., Callin)Pros and cons of marking up your own portfolio companies and mega-fund behavior (e.g., Andreessen, SoftBank)Zymergen’s implosion and the broader synthetic biology/deep-tech funding narrativeFraud, narrative-driven investing, and diligence failures (Theranos, Nikola, WeWork, Quibi, Tether)Fintech consolidation and strategy: Square’s acquisition of Afterpay, BNPL, and multi-product financial platformsFinancial deplatforming, payment-platform power, and regulatory/governance implications

In this episode of All-In Podcast, featuring Chamath Palihapitiya and David Sacks, E43: Innovative venture strategies, Zymergen's implosion, Square acquires Afterpay & more explores venture Studios, Deep Tech Busts, and Fintech Power Plays Unpacked The hosts open with updates on their own investment vehicles: Friedberg’s Production Board venture studio raise with Alphabet and top institutions, and Sacks’ $1.12B Craft Ventures fund focused on SaaS and marketplaces. They debate the merits of the venture studio model, concentration versus spraying capital, and how incubating companies fits into LP agreements.

At a glance

WHAT IT’S REALLY ABOUT

Venture Studios, Deep Tech Busts, and Fintech Power Plays Unpacked

  1. The hosts open with updates on their own investment vehicles: Friedberg’s Production Board venture studio raise with Alphabet and top institutions, and Sacks’ $1.12B Craft Ventures fund focused on SaaS and marketplaces. They debate the merits of the venture studio model, concentration versus spraying capital, and how incubating companies fits into LP agreements.
  2. A major segment dissects Zymergen’s IPO implosion as a case study in deep-tech hype without product–market fit, comparing it to Theranos, Nikola, WeWork, and Quibi, and emphasizing the importance of milestones, honest metrics, and governance. They explore how frothy capital, SoftBank-style mega-checks, and narrative-driven investing let deep-tech stories outrun reality and hurt employees.
  3. The conversation then turns to fintech consolidation: Square’s $29B all-stock acquisition of Afterpay, the economics of “buy now, pay later,” and how players like Square, PayPal, Stripe, and Shopify can convert costs into revenue lines and build multi-product financial super-apps. They also flag growing concerns over financial deplatforming, with PayPal and Square’s policies raised as potential threats to access to finance.
  4. Throughout, they weave in personal war stories (Theranos, Tether, Robinhood, Tesla, Virgin Galactic) to illustrate how investors should think about diligence, fraud risk, and the difference between early-stage narrative bets and massive capital allocations.

IDEAS WORTH REMEMBERING

7 ideas

Hyper-focused venture studios can be attractive if they combine domain expertise with patient capital.

Friedberg’s Production Board focuses tightly on synthetic biology and deep tech, using a holding-company structure and long-term institutional LPs (Alphabet, BlackRock, Cascade, etc.) to support a small number of hard companies through long R&D cycles without being forced into premature venture rounds or artificial markups.

In deep tech, product–market fit and unit economics still trump platform stories.

Zymergen spent years as a services platform and then pivoted to products, but never achieved compelling economics or customer demand; the hosts argue that no amount of robotic labs, SoftBank money, or synthetic-biology rhetoric compensates for not having paying customers and viable gross margins.

Narratives are useful at seed, but dangerous when attached to massive checks without proof.

The group distinguishes between small, early “narrative bets” (where uncertainty is expected) and writing $100M–$500M checks or IPO-ing companies without milestones; they see SoftBank-style mega-rounds and self-markups as inviting governance failures, excess cash, and eventual blowups.

Disciplined, metric-driven diligence can prevent many high-profile investment disasters.

Sacks emphasizes always seeing core SaaS metrics (ARR, churn, NRR, CAC) and product demos before investing, while Calacanis notes that 20–30% of seemingly strong startups fail basic diligence (cap tables, accounting, IP, recurring vs. one-off revenue), underscoring that simple checks catch a lot of risk.

Massive valuations without skin in the game and real governance increase fraud risk.

Chamath stresses that when investors deploy other people’s money without personal downside, they are more likely to overlook red flags (Theranos, Nikola, Zymergen); robust boards, diverse investors, and founders with meaningful personal capital at risk reduce the chance of narrative-driven fraud.

Fintech winners will likely be multi-product platforms that turn costs into revenue lines.

Using Amazon as a template (AWS, Prime, payments), they argue that companies like Square, Shopify, and others that keep adding adjacent financial features (BNPL, lending, trading, crypto, insurance) and convert internal cost centers into external services will compound value and be rewarded by public markets.

Financial deplatforming by large payment platforms may become a major policy battle.

Sacks warns that PayPal’s and Square’s willingness to ban users based on third-party “hate/extremism” lists extends social-media style censorship into finance, potentially denying people livelihoods; he expects future political and regulatory pushback, likening the needed response to a modern Teddy Roosevelt trust-busting era.

WORDS WORTH SAVING

6 quotes

For me, it’s not about how many businesses you start; it’s about absolute value creation.

David Friedberg

I think the best venture firms shouldn’t give a shit about any one company… their job is to pound money in, raise more money fast, and return market beta plus a little alpha.

Chamath Palihapitiya

In deep tech you can’t just say, ‘I’m going from zero to one with billions of dollars over decades’—that’s a government program, not a startup.

David Sacks

Humans want to believe. When you have a compelling narrative and a compelling deliverer of that narrative, you want to write a check.

David Friedberg

Square just acquired a $30 billion company for free—the market cap went up more than the purchase price.

Chamath Palihapitiya

The VC process revolves around a pitch. After reading Sapiens I asked, ‘How do I get out of a narrative-driven investing philosophy?’

David Sacks

QUESTIONS ANSWERED IN THIS EPISODE

5 questions

How should LPs and boards structure governance so that deep-tech companies can pursue long, risky R&D without slipping into overhyped narratives and misrepresentation?

The hosts open with updates on their own investment vehicles: Friedberg’s Production Board venture studio raise with Alphabet and top institutions, and Sacks’ $1.12B Craft Ventures fund focused on SaaS and marketplaces. They debate the merits of the venture studio model, concentration versus spraying capital, and how incubating companies fits into LP agreements.

At what stage and check size should investors demand rigorous, milestone-based proof instead of primarily backing a founder’s story?

A major segment dissects Zymergen’s IPO implosion as a case study in deep-tech hype without product–market fit, comparing it to Theranos, Nikola, WeWork, and Quibi, and emphasizing the importance of milestones, honest metrics, and governance. They explore how frothy capital, SoftBank-style mega-checks, and narrative-driven investing let deep-tech stories outrun reality and hurt employees.

How can employees better protect themselves from tax and liquidity disasters like Zymergen’s, where option exercises and IPO hype leave them owing money on collapsing stock?

The conversation then turns to fintech consolidation: Square’s $29B all-stock acquisition of Afterpay, the economics of “buy now, pay later,” and how players like Square, PayPal, Stripe, and Shopify can convert costs into revenue lines and build multi-product financial super-apps. They also flag growing concerns over financial deplatforming, with PayPal and Square’s policies raised as potential threats to access to finance.

Will the growing consolidation in fintech—acquisitions like Square–Afterpay and eventual banking licenses—lead to healthier competition or dangerous concentrations of financial power?

Throughout, they weave in personal war stories (Theranos, Tether, Robinhood, Tesla, Virgin Galactic) to illustrate how investors should think about diligence, fraud risk, and the difference between early-stage narrative bets and massive capital allocations.

Where should the line be drawn between private platforms’ right to set policies and the public’s right to access speech and financial infrastructure in an increasingly digital economy?

EVERY SPOKEN WORD

Install uListen for AI-powered chat & search across the full episode — Get Full Transcript

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome